These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10871245)

  • 41. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis and disease modifying treatments in multiple sclerosis.
    Zajicek J
    Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment.
    Shipova EG; Spirin NN; Kasatkin DS; Shumakov EI; Stepanov IO
    Neurosci Behav Physiol; 2009 Jan; 39(1):47-51. PubMed ID: 19089623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
    Goodin DS; Bates D
    Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple sclerosis treatment 2001.
    Rolak LA
    Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
    Ghezzi A; Amato MP; Annovazzi P; Capobianco M; Gallo P; La Mantia L; Marrosu MG; Martinelli V; Milani N; Moiola L; Patti F; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Neurol Sci; 2009 Jun; 30(3):193-9. PubMed ID: 19387545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
    Romeo M; Martinelli-Boneschi F; Rodegher M; Esposito F; Martinelli V; Comi G;
    Eur J Neurol; 2013 Jul; 20(7):1060-7. PubMed ID: 23425504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapies in multiple sclerosis.
    Gold R
    J Neurol; 2008 Mar; 255 Suppl 1():51-60. PubMed ID: 18317677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of immunomodulatory treatment on multiple sclerosis fatigue.
    Metz LM; Patten SB; Archibald CJ; Bakker JI; Harris CJ; Patry DG; Bell RB; Yeung M; Murphy WF; Stoian CA; Billesberger K; Tillotson L; Peters S; McGowan D
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1045-7. PubMed ID: 15201369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Early immunomodulatory treatment of multiple sclerosis: pros and cons].
    Wender M
    Neurol Neurochir Pol; 2003; 37(4):777-82. PubMed ID: 14746238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].
    Demina TL; Khachanova NV; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(3):15-9. PubMed ID: 16608106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.